WallStSmart

Precision BioSciences Inc (DTIL)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 1670% more annual revenue ($606.42M vs $34.26M). INSM leads profitability with a -2.1% profit margin vs -133.5%. DTIL earns a higher WallStSmart Score of 45/100 (D+).

DTIL

Hold

45

out of 100

Grade: D+

Growth: 7.3Profit: 4.0Value: 5.0Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DTIL3 strengths · Avg: 9.3/10
Operating MarginProfitability
36.6%10/10

Strong operational efficiency at 36.6%

Revenue GrowthGrowth
52.6%10/10

Revenue surging 52.6% year-over-year

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

DTIL4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$161.22M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-62.7%2/10

ROE of -62.7% — below average capital efficiency

Free Cash FlowQuality
$-11.28M2/10

Negative free cash flow — burning cash

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : DTIL

The strongest argument for DTIL centers on Operating Margin, Revenue Growth, Price/Book. Revenue growth of 52.6% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : DTIL

The primary concerns for DTIL are EPS Growth, Market Cap, Return on Equity.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

DTIL profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

DTIL carries more volatility with a beta of 1.32 — expect wider price swings.

DTIL is growing revenue faster at 52.6% — sustainability is the question.

DTIL generates stronger free cash flow (-11M), providing more financial flexibility.

Bottom Line

DTIL scores higher overall (45/100 vs 39/100) and 52.6% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Precision BioSciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?